Literature DB >> 29272467

Hippocampal Subregions Across the Psychosis Spectrum.

Teresa Vargas1, Derek J Dean2, Kenneth Juston Osborne1, Tina Gupta1, Ivanka Ristanovic1, Sekine Ozturk1, Jessica Turner3, Theo G M van Erp4, Vijay Anand Mittal1.   

Abstract

Introduction: Converging evidence suggests that hippocampal subregions subserve different functions, and are differentially affected by psychosis illness progression. Despite this fact, studies have not often studied subregions cross-sectionally across the psychosis spectrum. Furthermore, little is known about associations between subregion volumes and hippocampus-mediated cognition.
Methods: A total of 222 participants (61 ultra high risk [UHR], 91 schizophrenia [SCZ], and 70 healthy volunteers) underwent a 3T MRI scan, as well as structured clinical interviews and a cognitive battery. Hippocampal subfield analysis was conducted with Freesurfer. We compared subregion volumes across groups, controlling for age, gender, and intracranial volume. We also examined associations in the UHR and SCZ groups between hippocampal subregion volumes and verbal learning, visual learning, and working memory.
Results: We found a dose-dependent relationship such that the SCZ group showed significantly greater subfield volume reductions than the UHR group, which in turn showed significantly greater subfield volume reductions than the healthy volunteer group. We also found associations between subregion volume and cognitive performance in the visual memory, verbal memory, and working memory domains. Discussion: Our study examined hippocampal subregion volumes cross-sectionally in a large sample across the psychosis spectrum, as well as links with hippocampus-mediated cognitive function. Our findings suggest that hippocampal abnormalities emerge before first psychosis episode onset, and may be etiologically informative.

Entities:  

Mesh:

Year:  2018        PMID: 29272467      PMCID: PMC6101630          DOI: 10.1093/schbul/sbx160

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  58 in total

Review 1.  The stressed hippocampus, synaptic plasticity and lost memories.

Authors:  Jeansok J Kim; David M Diamond
Journal:  Nat Rev Neurosci       Date:  2002-06       Impact factor: 34.870

2.  Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls.

Authors:  Dwight Dickinson; Terry E Goldberg; James M Gold; Brita Elvevåg; Daniel R Weinberger
Journal:  Schizophr Bull       Date:  2010-03-29       Impact factor: 9.306

3.  Heritability of Hippocampal Formation Sub-region Volumes.

Authors:  Kiefer S Greenspan; Claire R Arakelian; Theo G M van Erp
Journal:  J Neurol Neurosci       Date:  2016-11-14

4.  In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder.

Authors:  Unn K Haukvik; Lars T Westlye; Lynn Mørch-Johnsen; Kjetil N Jørgensen; Elisabeth H Lange; Anders M Dale; Ingrid Melle; Ole A Andreassen; Ingrid Agartz
Journal:  Biol Psychiatry       Date:  2014-07-03       Impact factor: 13.382

5.  Hippocampal deformities in schizophrenia characterized by high dimensional brain mapping.

Authors:  John G Csernansky; Lei Wang; Donald Jones; Devna Rastogi-Cruz; Joel A Posener; Gitry Heydebrand; J Philip Miller; Michael I Miller
Journal:  Am J Psychiatry       Date:  2002-12       Impact factor: 18.112

6.  Amygdala-hippocampal volume and verbal memory in first-degree relatives of schizophrenic patients.

Authors:  G A O'Driscoll; P S Florencio; D Gagnon; A V Wolff; C Benkelfat; L Mikula; S Lal; A C Evans
Journal:  Psychiatry Res       Date:  2001-08-25       Impact factor: 3.222

7.  Hippocampal volume development in healthy siblings of childhood-onset schizophrenia patients.

Authors:  Anand Mattai; Avinash Hosanagar; Brian Weisinger; Deanna Greenstein; Reva Stidd; Liv Clasen; Francois Lalonde; Judith Rapoport; Nitin Gogtay
Journal:  Am J Psychiatry       Date:  2011-01-18       Impact factor: 18.112

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.

Authors:  Ian Mathew; Tova M Gardin; Neeraj Tandon; Shaun Eack; Alan N Francis; Larry J Seidman; Brett Clementz; Godfrey D Pearlson; John A Sweeney; Carol A Tamminga; Matcheri S Keshavan
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

10.  Progressive Decline in Hippocampal CA1 Volume in Individuals at Ultra-High-Risk for Psychosis Who Do Not Remit: Findings from the Longitudinal Youth at Risk Study.

Authors:  New Fei Ho; Daphne J Holt; Mike Cheung; Juan Eugenio Iglesias; Alex Goh; Mingyuan Wang; Joseph Kw Lim; Joshua de Souza; Joann S Poh; Yuen Mei See; Alison R Adcock; Stephen J Wood; Michael Wl Chee; Jimmy Lee; Juan Zhou
Journal:  Neuropsychopharmacology       Date:  2017-01-12       Impact factor: 7.853

View more
  22 in total

1.  The need to develop personalized interventions to improve cognition in schizophrenia.

Authors:  Peter Falkai; Andrea Schmitt
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 2.  Stress during critical periods of development and risk for schizophrenia.

Authors:  Felipe V Gomes; Xiyu Zhu; Anthony A Grace
Journal:  Schizophr Res       Date:  2019-01-30       Impact factor: 4.939

3.  Timing of menarche and abnormal hippocampal connectivity in youth at clinical-high risk for psychosis.

Authors:  Katherine S F Damme; Ivanka Ristanovic; Teresa Vargas; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2020-04-30       Impact factor: 4.905

4.  A web-based adapted physical activity program (e-APA) versus health education program (e-HE) in patients with schizophrenia and healthy volunteers: study protocol for a randomized controlled trial (PEPSY V@Si).

Authors:  Maxime Tréhout; Elise Leroux; Lucile Bigot; Solenne Jego; Pascal Leconte; Emmanuel Reboursière; Rémy Morello; Pierre-Alexandre Chapon; Aline Herbinet; Gaëlle Quarck; Sonia Dollfus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-26       Impact factor: 5.270

5.  Global and Specific Cortical Volume Asymmetries in Individuals With Psychosis Risk Syndrome and Schizophrenia: A Mixed Cross-sectional and Longitudinal Perspective.

Authors:  Katherine S F Damme; Teresa Vargas; Vince Calhoun; Jessica Turner; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

6.  Sensorimotor and Activity Psychosis-Risk (SMAP-R) Scale: An Exploration of Scale Structure With Replication and Validation.

Authors:  Katherine S F Damme; Jason Schiffman; Lauren M Ellman; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

7.  Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment.

Authors:  Xiaoe Lang; Dongmei Wang; Dachun Chen; Meihong Xiu; Huixia Zhou; Li Wang; Bo Cao; Xiangyang Zhang
Journal:  Neurotherapeutics       Date:  2022-01-31       Impact factor: 6.088

8.  Anterior vs Posterior Hippocampal Subfields in an Extended Psychosis Phenotype of Multidimensional Schizotypy in a Nonclinical Sample.

Authors:  Lili Sahakyan; Tina Meller; Ulrika Evermann; Simon Schmitt; Julia-Katharina Pfarr; Jens Sommer; Thomas R Kwapil; Igor Nenadić
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

9.  Psychosis risk individuals show poor fitness and discrepancies with objective and subjective measures.

Authors:  David Kimhy; Vijay A Mittal; Katherine S F Damme; Richard P Sloan; Matthew N Bartels; Alara Ozsan; Luz H Ospina
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

10.  Cannabidiol modulation of hippocampal glutamate in early psychosis.

Authors:  Aisling O'Neill; Luciano Annibale; Grace Blest-Hopley; Robin Wilson; Vincent Giampietro; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2021-04-16       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.